| scholarly article | Q13442814 |
| P2093 | author name string | Julie L. Bronder | |
| Richard G. Moran | |||
| P2860 | cites work | Cancer Research | Q326097 |
| The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases | Q24319848 | ||
| Acetylation of histones and transcription-related factors | Q24548503 | ||
| Regulation of p53 function and stability by phosphorylation | Q24554530 | ||
| UV Irradiation Stimulates Levels of p53 Cellular Tumor Antigen in Nontransformed Mouse Cells | Q24609948 | ||
| Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain | Q27860534 | ||
| WAF1, a potential mediator of p53 tumor suppression | Q27861121 | ||
| DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2 | Q28254119 | ||
| p21 is a universal inhibitor of cyclin kinases | Q28257305 | ||
| Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation | Q28369825 | ||
| DNA damage activates p53 through a phosphorylation–acetylation cascade | Q29616294 | ||
| mdm2 expression is induced by wild type p53 activity | Q29618316 | ||
| In vivo cross-linking and immunoprecipitation for studying dynamic Protein:DNA associations in a chromatin environment | Q30304486 | ||
| Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents | Q32062474 | ||
| Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks | Q33332394 | ||
| Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis | Q33493629 | ||
| A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. | Q33497955 | ||
| Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. | Q34011633 | ||
| Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin | Q34051350 | ||
| p53 accumulates but is functionally impaired when DNA synthesis is blocked | Q34641149 | ||
| Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion | Q35107974 | ||
| DNA damage induces phosphorylation of the amino terminus of p53 | Q35199554 | ||
| Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid | Q35977618 | ||
| A minimal Bcl-x promoter is activated by Brn-3a and repressed by p53 | Q39489233 | ||
| Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells | Q39701943 | ||
| ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation | Q40747424 | ||
| A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation | Q40800224 | ||
| Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. | Q40911658 | ||
| AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase | Q41244479 | ||
| DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation | Q42816808 | ||
| Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase | Q44375797 | ||
| A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. | Q45985375 | ||
| Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment | Q52590496 | ||
| DNA repair induction by cytostatic drugs in proliferating and quiescent MRC-5 cells | Q72721318 | ||
| p53 and WAF1 are induced and Rb protein is hypophosphorylated during cell growth inhibition by the thymidylate synthase inhibitor ZD1694 (Tomudex) | Q73231810 | ||
| An inhibitor of glycinamide ribonucleotide formyltransferase is selectively cytotoxic to cells that lack a functional G1 checkpoint | Q74094371 | ||
| Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases | Q77456357 | ||
| Phosphorylation of p53 serine 15 increases interaction with CBP | Q77604720 | ||
| P433 | issue | 49 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biochemistry | Q7094 |
| cell biology | Q7141 | ||
| P304 | page(s) | 48861-48871 | |
| P577 | publication date | 2003-09-29 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | A defect in the p53 response pathway induced by de novo purine synthesis inhibition | |
| A Defect in the p53 Response Pathway Induced by de Novo Purine Synthesis Inhibition | |||
| P478 | volume | 278 |
| Q36421452 | A mouse gene that coordinates epigenetic controls and transcriptional interference to achieve tissue-specific expression |
| Q36282831 | AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells |
| Q30837066 | Bayesian pathway analysis of cancer microarray data |
| Q28552611 | Ceramide Synthase 6 Is a Novel Target of Methotrexate Mediating Its Antiproliferative Effect in a p53-Dependent Manner |
| Q38718741 | Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates |
| Q44952054 | Imbalanced base excision repair in response to folate deficiency is accelerated by polymerase beta haploinsufficiency |
| Q39852820 | Inhibition of de novo purine synthesis in human prostate cells results in ATP depletion, AMPK activation and induces senescence |
| Q98665136 | Integrated proteomics and metabolomics reveals the comprehensive characterization of antitumor mechanism underlying Shikonin on colon cancer patient-derived xenograft model |
| Q91833664 | Loss of ALDH1L1 folate enzyme confers a selective metabolic advantage for tumor progression |
| Q36169303 | Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer |
| Q28238740 | Phylogenetic analysis and in silico characterization of the GARS-AIRS-GART gene which codes for a tri-functional enzyme protein involved in de novo purine biosynthesis |
| Q37326960 | Polyamine biosynthesis impacts cellular folate requirements necessary to maintain S-adenosylmethionine and nucleotide pools. |
| Q34128798 | Reversal of TNP-470-induced endothelial cell growth arrest by guanine and guanine nucleosides |
| Q34297931 | The human proton-coupled folate transporter: Biology and therapeutic applications to cancer |
| Q37663377 | The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer |
| Q50062142 | The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer |
| Q40568020 | Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. |
| Q35086367 | Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance |
| Q43084695 | p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb |
| Q42098836 | p53-Dependent p21 mRNA elongation is impaired when DNA replication is stalled. |
Search more.